Table 5.
DEX implant in Coats’ disease
| Reference | Study design | No of eyes | Previous treatment | Primary treatment | Follow-up | Retreatment | BCVA | CMT | Complications |
|---|---|---|---|---|---|---|---|---|---|
| Saatci et al60 | Case report | 2 | 5 ranibizumab IVT + laser photocoagulation in 1 eye | DEX in one patient DEX + laser photocoagulation in the other patient |
12 months 6 months |
NR | Unchanged From 2/10 to 3/10 |
NR | IOP rise >25 mmHg in both eyes |
| Martínez-Castillo et al61 | Case report | 1 | None | DEX + laser photocoagulation | 12 months | NR | From 20/200 to 20/25 | NR | None |
| Lei and Lam62 | Retrospective chart review | 1 | 3 BEV IVT + laser photocoagulation | DEX | 16 months | 3 DEX | From 1.3 to 52 weeks: 1.8 logMAR | From 821 μm to 52 weeks: 589 μm | None |
Abbreviations: BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; NR, not reported.